军事知识服务平台
天麦消渴片治疗中国新诊断2型糖尿病患者的疗效研究
Efficacy of fianmaixiaoke tablets in the treatment of newly diagnosed type 2 diabetes mellitus in China
摘要 目的 分析天麦消渴片治疗新诊断2型糖尿病患者的疗效及影响因素.方法 纳入符合条件的2型糖尿病患者84例,采用区组随机化分为2组:试验组42例,口服天麦消渴片240mg/次,每日2次;对照组42例,口服西格列汀(捷诺维)100 mg/d.治疗24周后以糖化血红蛋白(HbA1c)、空腹血糖(FPG)及餐后2h血糖(PG2 h)、血清铬水平等评价服用天麦消渴片的有效性,同时通过测定胰岛素抵抗和β细胞功能的指标,探讨补铬改善血糖的作用机制.应用多因素线性回归分析各因素与HbA1c变化之间的关系.结果 入组84例,76例完成了试验.治疗前糖尿病组血清铬水平显著低于正常对照组[(56±28)μg/L比(112±21) μg/L,P=0.00].治疗24周后,两组HbA1c,FPG和PG2 h较前均显著降低,血清铬水平显著增加.天麦消渴片组治疗后HbA1c下降≥1%者11例(占28.2%),基线血清铬水平较低,用药24周后升高[(36.2±18.0)μg/L比(71.4±36.1)μg/L,P=0.01],同时HbA1c降低(8.38%±0.72%比6.77%±0.62%),降幅达1.61%.两组按基线血清铬水平分3个亚组,分别为<40μg/L,40 ~65 μg/L和>65 μg/L.当血清铬<40 μg/L时,天麦消渴片组HbA1c显著降低,下降幅度为1.09%;当血清铬>65 μg/L时,HbA1c无显著变化.西格列汀组HbA1c变化值(△HbA1c)与基线血清铬水平无关.治疗24周后,两组胰岛素抵抗指数(HOMA-IR)均有所降低,β细胞功能指数(HOMA-β)和早相分泌指数(IGI)有所增加.各指数组间比较差异无统计学意义.多因素线性回归分析显示基线血铬、基线HbA1c与△HbA1c显著相关.结论 新诊断2型糖尿病患者体内普遍缺铬.补铬可使糖尿病患者HbA1c改善,当糖尿病患者血清铬低于40μg/L时,给予天麦消渴片补充铬至正常或略低于正常水平可使HbA1c显著降低.
Abstract:
Objective To explore the efficacy and influencing factors of chromium picolinate (tianmaixiaoke tablet) in the treatment of newly diagnosed type 2 diabetes mellitus in China.Methods A total of 84 outpatients with newly diagnosed type 2 diabetes mellitus visiting 4 hospitals in Beijing were randomly divided into two equal groups:study group receiving tianmaixiaoke tablet 240 mg bid for 24 weeks (n=42) and control group sitagliptin 100 mg qd for 24 weeks (n =42).The levels of fasting plasma glucose (FPG),plasma glucose 2 h after meal (PG2 h) and glycated hemoglobin (HbA1c) were detected before and 24 weeks after treatment.The serum levels of chromium and insulin were detected.Results Study was completed in 76 patients.The serum level of chromium was significantly lower in the diabetes group than in the normal group at baseline ( (56 ±28) μg/L vs ( 112 ±21 ) μg/L,P =0.00).At 24 weeks after treatment,the levels of HbA1c,FPG and PG2 h decreased while the serum level of chromium increased significantly in both groups.There were 11 patients with changed HbA1c from baseline (△HbA1c) ≥1% in the study group.At 24 weeks after treatment,HbA1c decreased by 1.61% (from 8.38% ± 0.72% to 6.77% ±0.62% ) and serum level of chromium increased by 35.14 μg/L in the △HbA1c≥1% group with a low baseline serum level of chromium ( (36.2 ± 18.0) μg/L).Both study group and control group were divided into three subgroups according to baseline serum level of chromium. △HbA1c reduced with the increase in baseline serum level of chromium in study group,while in control group,△HbA1c was unrelated with baseline serum level of chromium.At 24 weeks after treatment,insulin resistance index (HOMA-IR)reduced,β cell function index (HOMA-β) and insulinogenic index (IGI) increased in both groups.Multiple linear regression showed that the variables significantly associated with △HbA1c were baseline HbA1c and the baseline serum level of chromium.Conclusions Chromium is commonly deficient in the newly diagnosed type 2 diabetics in China. HbA1c decreases and serum chromium increases significantly after chromium supplementation in the patients with a low baseline serum level of chromium.
Author: SHAO Cong LV Xiao-feng XIAO Xin-hua XU Zhang-rong YANG Zhao-jun WANG Peng LIU Xue-li YANG Wen-ying
作者单位: 100730,中国医学科学院北京协和医学院研究生院 北京军区总医院内分泌科 中国医学科学院北京协和医学院北京协和医院内分泌科 解放军第三○六医院内分泌科 中日友好医院内分泌科
刊 名 中华医学杂志 ISTICPKU
年,卷(期): 2012, 92(22)
分类号: R4
机标分类号: R563 R76 S831
在线出版日期: 2012年8月31日